Literature DB >> 7826350

Multiple substitutions at position 104 of beta-lactamase TEM-1: assessing the role of this residue in substrate specificity.

A Petit1, L Maveyraud, F Lenfant, J P Samama, R Labia, J M Masson.   

Abstract

Residue 104 is frequently mutated from a glutamic acid to a lysine in the extended-spectrum TEM beta-lactamases responsible for the resistance to third-generation cephalosporins in clinical Gram negative strains. Among class A beta-lactamases, it is the most variable residue within a highly conserved loop which delineates one side of the active site of the enzymes. To investigate the role of this residue in the extended-spectrum phenotype, it has been replaced by serine, threonine, lysine, arginine, tyrosine and proline. All these substitutions yield active enzymes, with no drastic changes in kinetic properties compared with the wild-type enzyme, except with cefaclor, but an overall improved affinity for second- and third-generation cephalosporins. Only mutant E104K exhibits a significant ability to hydrolyse cefotaxime. Molecular modelling shows that the substitutions have generally no impact on the conformation of the 101-111 loop as the side chains of residues at position 104 are all turned towards the solvent. Unexpectedly, the E104P mutant turns out to be the most efficient enzyme. All our results argue in favour of an indirect role for this residue 104 in the substrate specificity of the class A beta-lactamases. This residue contributes to the precise positioning of residues 130-132 which are involved in substrate binding and catalysis. Changing residue 104 could also modify slightly the local electrostatic potential in this part of the active site. The limited kinetic impact of the mutations at this position have to be analysed in the context of the microbiological problem of resistance to third-generation cephalosporins. Although mutation E104K improves the ability of the enzyme to hydrolyse these compounds, it is not sufficient to confer true resistance, and is always found in clinical isolates associated with at least one mutation at another part of the active site. It is the combined effect of the two mutations that synergistically enhances the hydrolytic capability of the enzyme towards third-generation cephalosporins.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7826350      PMCID: PMC1136426          DOI: 10.1042/bj3050033

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  26 in total

1.  Development of "oligotyping" for characterization and molecular epidemiology of TEM beta-lactamases in members of the family Enterobacteriaceae.

Authors:  C Mabilat; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  A standard numbering scheme for the class A beta-lactamases.

Authors:  R P Ambler; A F Coulson; J M Frère; J M Ghuysen; B Joris; M Forsman; R C Levesque; G Tiraby; S G Waley
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

3.  Probing the active site of beta-lactamase R-TEM1 by informational suppression.

Authors:  F Lenfant; R Labia; J M Masson
Journal:  Biochimie       Date:  1990 Jun-Jul       Impact factor: 4.079

4.  The diversity of the catalytic properties of class A beta-lactamases.

Authors:  A Matagne; A M Misselyn-Bauduin; B Joris; T Erpicum; B Granier; J M Frère
Journal:  Biochem J       Date:  1990-01-01       Impact factor: 3.857

5.  Substitution of serine for arginine in position 162 of TEM-type beta-lactamases extends the substrate profile of mutant enzymes, TEM-7 and TEM-101, to ceftazidime and aztreonam.

Authors:  E Collatz; G Tran Van Nhieu; D Billot-Klein; R Williamson; L Gutmann
Journal:  Gene       Date:  1989-05-30       Impact factor: 3.688

6.  Sequence and molecular characterization of the ROB-1 beta-lactamase gene from Pasteurella haemolytica.

Authors:  V Livrelli; J Peduzzi; B Joly
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

7.  Characterization of the plasmid genes blaT-4 and blaT-5 which encode the broad-spectrum beta-lactamases TEM-4 and TEM-5 in enterobacteriaceae.

Authors:  W Sougakoff; A Petit; S Goussard; D Sirot; A Bure; P Courvalin
Journal:  Gene       Date:  1989-05-30       Impact factor: 3.688

8.  Substitution of lysine at position 104 or 240 of TEM-1pTZ18R beta-lactamase enhances the effect of serine-164 substitution on hydrolysis or affinity for cephalosporins and the monobactam aztreonam.

Authors:  J A Sowek; S B Singer; S Ohringer; M F Malley; T J Dougherty; J Z Gougoutas; K Bush
Journal:  Biochemistry       Date:  1991-04-02       Impact factor: 3.162

9.  Crystal structure of Escherichia coli TEM1 beta-lactamase at 1.8 A resolution.

Authors:  C Jelsch; L Mourey; J M Masson; J P Samama
Journal:  Proteins       Date:  1993-08

10.  Molecular structure of the acyl-enzyme intermediate in beta-lactam hydrolysis at 1.7 A resolution.

Authors:  N C Strynadka; H Adachi; S E Jensen; K Johns; A Sielecki; C Betzel; K Sutoh; M N James
Journal:  Nature       Date:  1992-10-22       Impact factor: 49.962

View more
  24 in total

1.  Characterization of TEM-56, a novel beta-lactamase produced by a Klebsiella pneumoniae clinical isolate.

Authors:  C Neuwirth; R Labia; E Siebor; A Pechinot; S Madec; E B Chaibi; A Kazmierczak
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Mutant TEM beta-lactamase producing resistance to ceftazidime, ampicillins, and beta-lactamase inhibitors.

Authors:  Sergei Vakulenko; Dasantila Golemi
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

3.  Network Analysis of Sequence-Function Relationships and Exploration of Sequence Space of TEM β-Lactamases.

Authors:  Catharina Zeil; Michael Widmann; Silvia Fademrecht; Constantin Vogel; Jürgen Pleiss
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Use of novel boronic acid transition state inhibitors to probe substrate affinity in SHV-type extended-spectrum beta-lactamases.

Authors:  Jodi M Thomson; Fabio Prati; Christopher R Bethel; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

5.  Negative Epistasis and Evolvability in TEM-1 β-Lactamase--The Thin Line between an Enzyme's Conformational Freedom and Disorder.

Authors:  Eynat Dellus-Gur; Mikael Elias; Emilia Caselli; Fabio Prati; Merijn L M Salverda; J Arjan G M de Visser; James S Fraser; Dan S Tawfik
Journal:  J Mol Biol       Date:  2015-05-22       Impact factor: 5.469

6.  Role of SHV β-lactamase variants in resistance of clinical Klebsiella pneumoniae strains to β-lactams in an Algerian hospital.

Authors:  Nadjia Ramdani-Bouguessa; Vera Manageiro; Daniela Jones-Dias; Eugénia Ferreira; Mohamed Tazir; Manuela Caniça
Journal:  J Med Microbiol       Date:  2011-03-17       Impact factor: 2.472

Review 7.  Catalytic properties of class A beta-lactamases: efficiency and diversity.

Authors:  A Matagne; J Lamotte-Brasseur; J M Frère
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

8.  Novel extended-spectrum TEM-type beta-lactamase from an Escherichia coli isolate resistant to ceftazidime and susceptible to cephalothin.

Authors:  C Chanal-Claris; D Sirot; L Bret; P Chatron; R Labia; J Sirot
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

9.  High tolerance to simultaneous active-site mutations in TEM-1 beta-lactamase: Distinct mutational paths provide more generalized beta-lactam recognition.

Authors:  Pierre-Yves De Wals; Nicolas Doucet; Joelle N Pelletier
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

10.  Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155.

Authors:  C Hal Jones; Alexey Ruzin; Margareta Tuckman; Melissa A Visalli; Peter J Petersen; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.